EXTENDED REPORT

Long term effect on IOP of a stainless steel glaucoma drainage implant (Ex-PRESS) in combined surgery with phacoemulsification

C E Traverso, F De Feo, A Messas-Kaplan, P Denis, S Levartovsky, E Sellem, F Badalà, Z Zagorski, A Bron, M Belkin

Aim: To evaluate the efficacy and safety of a stainless steel miniature glaucoma drainage device (Ex-PRESS R50) for the surgical treatment of primary open angle glaucoma (POAG) and cataract when combined with phacoemulsification.

Methods: Clinical, prospective, multicentre, single treatment arm, non-randomised, non-masked study. The Ex-PRESS device was implanted at the limbus under a conjunctival flap. Phacoemulsification cataract extraction and in the bag IOL implantation were performed through clear cornea temporally. Primary outcome: IOP change; secondary outcomes: side effects and VA changes.

Results: 26 eyes of 25 patients were implanted with the device. The mean (SD) follow up was 23.9 (10.4) months and the mean age was 75.1 (7.1) years. 17/26 eyes have more than 3 years of follow up. One case was discontinued because of device removal, one because of death, and three were lost to follow up. Efficacy: preoperative IOP was 21 (4) mm Hg; at 1, 2, and 3 years IOP was 15.3 (3.1) mm Hg (35% reduction), 16.6 (2.7) mm Hg (29% reduction), and 16 (2.6) mm Hg (22% reduction) respectively. Kaplan-Meyer determined overall success rate (IOP < 21 mm Hg at the last visit with or without medications) as 76.9%. The number of antiglaucoma medications was reduced by 95% at year 1. Only six patients (23%) were taking IOP lowering treatment at their last visit, five with one medication and one with two medications. Side effects: early postoperative complications were clinically mild and included six cases of hypotony (IOP < 5 mm Hg), three cases of hyphaema (< 2 mm) with no clinically significant further effects. Long term complications were two cases (7.7%) of device rotation (one treated by reposition) and three cases (11.5%) of conjunctival erosion at 2 and 3 years.

Conclusions: The Ex-PRESS implant, combined with phacoemulsification cataract extraction, is clinically safe and effective, maintaining in the long term a large reduction in IOP and in the number of antiglaucoma medications.

The occurrence of both glaucoma and clinically relevant cataract in the same individual is a frequent condition, especially in the elderly population. Besides age, this might be related to the possible role of antiglaucoma medications in the progression of lens opacity. When both procedures are required, these can be performed separately or in combination.

Glaucoma filtering surgery is indicated when glaucomatous damage progresses despite the lower level of intraocular pressure (IOP) obtained with pharmacological and/or laser treatment. In the past few years, filtering surgery has improved, with an increased likelihood of successfully lowering the IOP while minimising complications. While full thickness filtration procedures considerably reduced the IOP, they were associated with early postoperative hypotony and related side effects and became progressively less popular.

Trabeculectomy has been the surgical treatment of choice for primary open angle glaucoma (POAG) since the 1970s; its success rates and complication however are less than ideal. Early hypotony and bleb infections are still of concern.

Glaucoma drainage implants, designed to shunt the aqueous posteriorly, represent an alternative method for lowering IOP in glaucomatous patients, commonly used in refractory glaucoma or after the failure of other surgical approaches.

The Ex-PRESS is a miniature stainless steel glaucoma device, developed as an alternative to trabeculectomy and to the other types of glaucoma filtering surgery for patients with POAG. This procedure would be theoretically more reproducible and simple to perform as well as less traumatic to the ocular tissue than traditional filtering surgery. The implant is inserted at the limbus under a conjunctival flap and diverts the aqueous humour from the anterior chamber to the subconjunctival space, obtaining the formation of a conjunctival filtration bleb, in a similar way to trabeculectomy. This procedure can be performed on its own or in combination with phacoemulsification.

This study is about the long term efficacy and safety results of the Ex-PRESS device (Optonol Ltd) implanted for the surgical treatment of POAG and cataract when combined with phacoemulsification.

PATIENTS AND METHODS

This non-randomised, multicentre, prospective trial was conducted at three different centres. All operations were performed by one experienced ophthalmic surgeon in each centre. Surgeons were instructed in the implantation procedure for the device and practised the procedure on animal eyes before operating on humans. Approval from the institutional review boards was obtained. After receiving a comprehensive explanation of the experimental nature of the study, patients signed informed consent to participate.

Abbreviations: 5-FU, 5-fluorouracil; CRF, case report forms; IOL, intraocular lens; IOP, intraocular pressure; POAG, primary open angle glaucoma

See end of article for authors’ affiliations

Correspondence to: Professor Carlo E Traverso, Department of Neurosciences, Ophthalmology and Genetics, University of Genova, Italy; mc86200@mdlink.it

Accepted for publication 1 December 2004
this procedure, informed consent was obtained from each patient.

Patients were recruited prospectively and non-consecutively. Their mean age was 75.1 (SD 7.1) years. Eligibility criteria included the presence of POAG, mobile unscarred conjunctiva for at least two clock hours superiorly, an indication for glaucoma filtering surgery based on uncontrolled IOP despite medications, and the presence of a clinically significant decrease of visual acuity as a result of cataract. Eyes with angle closure glaucoma, neovascular glaucoma, congenital or juvenile glaucoma, or monocular patients were excluded. All patients had ophthalmic examination within 6 months before the recruitment, and were affected by POAG.

Upon enrolment each patient underwent a complete ophthalmic examination; postoperative evaluations were performed on the first and seventh days and on the first, second, third, sixth, ninth, 12th, 18th, 24th, 30th, 36th, 42nd, and 48th postoperative months, or more often when required. The examination consisted of measurement of best corrected visual acuity, slit lamp biomicroscopy of the anterior and posterior segments, IOP measurement by applanation tonometry, and gonioscopy. History and all medication details were recorded. Standard case report forms (CRF) were used.

The Ex-PRESS R50 drainage device is an non-valved flow restricting implant, made of implantable stainless steel (316L), which is approved for medical and ophthalmic applications. The R50 device is built with a 3 mm long tube with a 400 μm (27 gauge) external diameter, a 50 μm inner diameter, and a bevelled, sharpened, rounded tip (fig 1). The disc-like flange at the device’s proximal end prevents it being implanted too deeply, while the spur-like projection prevents its extrusion. The external flange and inner spur are angled to conform to the anatomy of the sclera, and the distance between them corresponds to the scleral thickness at the limbus, where the device is implanted. Three holes around the proximal end of the device’s shaft ensure filtration if the main orifice becomes blocked by the iris or other tissues.

**Surgical technique**

The Ex-PRESS R50 device was implanted under local or topical anaesthesia, using standard ophthalmic microsurgical instruments. The procedure consisted of a 2–4 mm circumferential conjunctiva opening, 10–15 mm posterior to the limbus. The implant, mounted on its introducer, was slid under the conjunctiva and Tenon’s capsule and implanted radial to the limbus and parallel to the iris through a preincision with a 27 gauge needle. The introducer was then withdrawn. The conjunctiva was closed with a suture at the surgeon’s discretion. Manipulation of the conjunctiva during the introduction was limited to one or two clock hours. At the end of this procedure, a temporal clear cornea phacoemulsification cataract extraction with “in the bag” intraocular lens (IOL) insertion was performed. (A diagrammatic representation of the implant in place is shown in fig 2.)

CRF were used to collect data on the procedure, its duration, and any complications during surgery. Using a semiquantitative scale of 1–5 (where 1 = very easy or very well positioned and 5 = very difficult or very poorly positioned), the surgeon graded the ease of the insertion and positioning of the implant at the limbus. At each follow up, the surgeon carried out a complete ophthalmic examination, recording all data on the CRF, including anterior chamber depth, device position, presence or absence of the bleb, and visual acuity. The IOP and the use of antiglaucoma medications or other IOP reduction procedures during the follow up were primary outcome measures. Secondary outcome measures included the visual acuity and the occurrence of perioperative or postoperative complications.

The procedure was labelled an overall success when IOP was <21 mm Hg with or without antiglaucoma medications; a complete success was defined as an IOP <21 mm Hg without medications. Postoperative bleb management and scarring modulation with needling or 5-fluorouracil (5-FU) injections were not a criterion for failure.

Results were analysed on an “intent to treat” basis. Data were presented as mean (SD), unless otherwise specified. The Wilcoxon signed rank test was used to compare changes from baseline IOP and to compare the number of antiglaucoma medications used by the patient. Time to failure, defined as an IOP >21 mm Hg at two consecutive visits, IOP >21 mm Hg at the last visit, or a need for additional surgery, was evaluated using Kaplan-Meyer survival analysis. A p value of <0.05 was considered statistically significant for all analyses. Statistical analyses were carried out using the SPSS statistical package or Microsoft Excel.

**RESULTS**

The Ex-PRESS R50 device was implanted into 26 eyes of 25 white patients with POAG and cataract. The mean age of the patients was 75.1 (7.1) years; table 1 details other demographic data.

The mean follow up period was 30.2 (14.5) months. Twenty five patients completed 1 year, 18 patients 2 years,

<table>
<thead>
<tr>
<th>Table 1 Patients and methods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patients</strong></td>
</tr>
<tr>
<td>Number of eyes</td>
</tr>
<tr>
<td>Female 15 (57.7%)</td>
</tr>
<tr>
<td>Male 11 (42.3%)</td>
</tr>
<tr>
<td>Age (SD) (years)</td>
</tr>
<tr>
<td>Types of glaucoma</td>
</tr>
<tr>
<td>Primary open angle glaucoma</td>
</tr>
<tr>
<td>Pseudoxfoliative glaucoma</td>
</tr>
<tr>
<td>Ocular hypertension</td>
</tr>
</tbody>
</table>

Figure 1 Design of the Ex-PRESS miniature glaucoma implant.
nine patients 3 years, and four patients 4 years. Two subjects discontinued the study because of erosion followed by removal and four patients were lost to follow up.

Mean preoperative (baseline) IOP was 21 (SD 4) mm Hg; at 1, 2, and 3 years after surgery IOP was 15.3 (3.1) mm Hg (35% reduction), 16.6 (2.7) mm Hg (29% reduction), and 16 (2.6) mm Hg (22% reduction), respectively (table 2, fig 3). The overall success rate (IOP ≤ 21 mm Hg with or without medications) was 94.4% at 2 years (17/18 eyes) and 76.9% at last visit (20/26 eyes). The complete success rate (IOP ≤ 21 mm Hg without medications) was 66.7% at 2 years (12/18 eyes) and 65.4% (17/26 eyes) at last visit (table 3).

The reduction of antiglaucoma medication use recorded following implantation of the Ex-PRESS device was significant. Six patients were treated pharmacologically at their last visit: five were treated with one medication and one with two medications (fig 4).

Visual acuity improved in 21 eyes; no change in VA was recorded in four eyes (fig 5). In one patient visual acuity decreased at the last visit (one Snellen line decrease).

Bleb needling in the postoperative period was performed in seven eyes: six of them associated with 5-FU injection. One

---

**Table 2** Efficacy—IOP summary, long term

<table>
<thead>
<tr>
<th>No</th>
<th>IOP (mm Hg)</th>
<th>Mean</th>
<th>SD</th>
<th>Median</th>
<th>Min</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td>26</td>
<td>24.5</td>
<td>5.0</td>
<td>24</td>
<td>17</td>
<td>40</td>
</tr>
<tr>
<td>1st year</td>
<td>25</td>
<td>15.3</td>
<td>3.1</td>
<td>15</td>
<td>7</td>
<td>22</td>
</tr>
<tr>
<td>2nd year</td>
<td>18</td>
<td>16.7</td>
<td>2.7</td>
<td>17</td>
<td>13</td>
<td>25</td>
</tr>
<tr>
<td>3rd year</td>
<td>9</td>
<td>18.6</td>
<td>5.1</td>
<td>17</td>
<td>13</td>
<td>28</td>
</tr>
<tr>
<td>4th year</td>
<td>4</td>
<td>16</td>
<td>6.9</td>
<td>18</td>
<td>6</td>
<td>22</td>
</tr>
</tbody>
</table>

---

**Table 3** Success rate

<table>
<thead>
<tr>
<th>Target IOP</th>
<th>Overall success (with or without meds)</th>
<th>Complete success (without meds)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Success rate at 2 years (n = 18)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 21 mm Hg</td>
<td>17/18 (94.4%)</td>
<td>12/18 (66.7%)</td>
</tr>
<tr>
<td>&lt; 18 mm Hg</td>
<td>16/18 (88.9%)</td>
<td>11/18 (61.1%)</td>
</tr>
<tr>
<td>Success rate at last visit (n = 26)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 21 mm Hg</td>
<td>20/26 (76.9%)</td>
<td>17/26 (65.4%)</td>
</tr>
<tr>
<td>&lt; 18 mm Hg</td>
<td>19/26 (73.1%)</td>
<td>16/26 (61.5%)</td>
</tr>
</tbody>
</table>

---

**Table 4** Postoperative interventions

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Eyes</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-FU injection</td>
<td>1</td>
<td>3.8</td>
</tr>
<tr>
<td>Needling with 5-FU</td>
<td>6</td>
<td>23.1</td>
</tr>
<tr>
<td>Needling without 5-FU</td>
<td>1</td>
<td>3.8</td>
</tr>
<tr>
<td>Total</td>
<td>8</td>
<td>30.7</td>
</tr>
</tbody>
</table>

---

**Figure 3** Efficacy, IOP dynamics (p = 0.004 for IOP reduction > 20% paired t test).

**Figure 4** Number of medications over time (p = 0.0001 for IOP reduction in medications, paired t test). Six patients (23%) were treated with medications at their last visit; five were treated with one medication; and one with two medications.

**Figure 5** Visual acuity (VA) for patients with a minimum follow up of 2 months (n = 26). VA improvement in 21 eyes; no change in VA, four eyes; VA decrease, one eye (one Snellen line decrease).
further patient received an injection of 5-FU without bleb needling (table 4).

Short term complications included three cases of hyphaema (<2 mm), one in the first postoperative day, all spontaneously resolved within 1 week; two cases of device rotation, one noticed at the first at first postoperative month and immediately repositioned and one 2 years after surgery, which caused conjunctival erosion; three cases of erosion: one at the second year of follow up, still now under observation, two at the second and third year respectively, one followed by device removal and one by device replacement; one case of choroidal detachment, probably related to vigorous rubbing of the eye as reported by the patient, spontaneously resolved; one case of iris contact with the implant, at second postoperative month, without sequelae (table 5).

DISCUSSION

The implantation of the Ex-PRESS R50 miniature stainless steel glaucoma drainage device in 26 eyes of 25 patients combined with phacoemulsification cataract extraction produced a cumulative overall success rate of 76.9% using an IOP ≤21 mm Hg as an end point. Our success rate compares favourably with data reported in the literature for other filtering procedures: 50–100% for trabeculectomy,18–20 up to 87.5% for non-penetrating surgery,21 22 and 25–90% for other glaucoma drainage devices.23–25

Our results confirm those obtained in a small case series using a trabecular meshwork bypass shunt where IOP and glaucoma medications were reduced in patients who were followed for up to 9 months.26

In studies comparing viscosocanalostomy with trabeculectomy, the latter procedure has been shown to be more effective in controlling IOP while viscosocanalostomy had fewer postoperative complications.21 22 27–30 A study comparing trabeculectomy (retrospectively) in one eye and deep sclerectomy with collagen implant (prospectively) in the other eye of 20 patients found comparable success rates with IOP <21 mm Hg obtained in 40% of the deep sclerectomy eye group and 45% of the trabeculectomy eye group; comparable IOP reductions were also reported in a prospective study of 78 eyes.31 However, another study noted lower levels of IOP with trabeculectomy although there were fewer complications with deep sclerectomy.23 24 Preliminary results from a study comparing deep sclerectomy with Ex-PRESS implant surgery indicated that the two procedures were comparable at 6 months of follow up.34

In our study, implantation of the Ex-PRESS device produced a low rate of short term complications, such as a shallow or flat chamber and hyphaema, similar to other filtering surgeries; there were no long term complications. Only six patients in our study required antiglaucoma medications at their last visit; comparatively better than commonly reported after trabeculectomy.20 25

Bleb failure due to fibroblast proliferation is one of the main causes of failed filtration. In order to minimise the risk of scarring, the use of antimetabolites preoperatively and postoperatively is common.

CONCLUSIONS

In summary, results from our study demonstrate that implantation of the Ex-PRESS device is safe and is not associated with significant complications, both in short and long term. The cases of conjunctival erosion can be prevented by optimal intraoperative positioning of the device, mainly avoiding too anterior implantation. The correct positioning of the implant is the most crucial consideration for preventing complications.

This stainless steel device is safe and effective for reducing IOP and antiglaucoma medications in combination with cataract extraction.

Our results indicate that this procedure can be considered as an alternative to conventional filtering surgery for the control of IOP in patients with open angle glaucoma. However, further studies that directly compare the Ex-PRESS implant with trabeculectomy and other procedures are still required to assess precisely the role and relative advantages and disadvantages of each technique.

Table 5  Complications

<table>
<thead>
<tr>
<th>Complication</th>
<th>No (%)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyphaema &lt; 2 mm</td>
<td>3 (11.5)</td>
<td>1 day postop; all resolved spontaneously within 1 week</td>
</tr>
<tr>
<td>Device rotation</td>
<td>2 (7.7)</td>
<td>1 month postop treated by repositioning; 2 years postop followed by erosion and is under observation (see below)</td>
</tr>
<tr>
<td>Choroidal detachment</td>
<td>1 (3.8)</td>
<td>21 months postop, due to vigorous rubbing of the eye; spontaneously resolved</td>
</tr>
<tr>
<td>Device iris touch</td>
<td>1 (3.8)</td>
<td>2 months postop; calm eye</td>
</tr>
<tr>
<td>Device malposition</td>
<td>2 (7.7)</td>
<td>1.5 years postop spontaneously resolved; 2.5 years postop with erosion</td>
</tr>
<tr>
<td>Erosion</td>
<td>3 (11.5)</td>
<td>2 years postop associated with rotation and is under observation (see above); 2.5 and 3 years postop one followed by device removal and one by device replacement</td>
</tr>
<tr>
<td>Suture granuloma</td>
<td>1 (3.8)</td>
<td>2 months postop; spontaneously resolved</td>
</tr>
<tr>
<td>Visual acuity decrease</td>
<td>1 (3.8)</td>
<td></td>
</tr>
</tbody>
</table>

Authors’ affiliations

C E Traverso, F De Feo, F Badala, DiNOG, Clinica Oculistica, University of Genova, Italy

A Messas-Kaplan, Ophthalmology Department, Assaf Harofe Medical Center, Tsirin, Israel

P Denis, Hôpital Edouard Herriot, Lyon, France

S Levartovsky, Barzilay Medical Center, Ashkelon, Israel

E Sellem, Centre Ophthalmologique Kleber, Lyon, France

Z Zagorski, Ophthalmology Department, Lublin University Medical School, Lublin, Poland

A Bron, Ophthalmology Department, University Hospital CHU Dijon, France

M Belkin, Goldschleger Eye Research Institute, Tel Hashomer, Israel

Competing interests: Professor Carlo E Traverso is also a clinical investigator for other surgical drainage glaucoma devices.

Informed consent: Approved by local ethics committees.

Declared interests: Carlo E Traverso, Audrey Messas-Kaplan, Philippe Denis, Shmeul Levartovsky, Eric Sellem, Zbigniew Zagorski, and Alain Bron have received funding from Optonol Ltd as clinical investigators for carrying out this study. Michael Belkin has proprietary interest in Optonol Ltd.

This work was presented as a poster at the Association for Research in Vision and Ophthalmology Annual Meeting 25–29 April 2004, Ft Lauderdale, FL, USA.
REFERENCES

1 The Ocular Hypertension Treatment Study. A randomised trial determines that topical ocular hypotensive medication delays or prevents the onset of POAG. Arch Ophthalmol 2002;120:701–3.


Long term effect on IOP of a stainless steel glaucoma drainage implant (Ex-PRESS) in combined surgery with phacoemulsification

C E Traverso, F De Feo, A Messas-Kaplan, P Denis, S Levartovsky, E Sellem, F Badalà, Z Zagorski, A Bron and M Belkin

doi: 10.1136/bjo.2004.058032

Updated information and services can be found at:
http://bjo.bmj.com/content/89/4/425

These include:

References
This article cites 29 articles, 4 of which you can access for free at:
http://bjo.bmj.com/content/89/4/425#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Errata
An erratum has been published regarding this article. Please see next page or:
http://bjo.bmj.com/content/89/5/645.3.full.pdf

Topic Collections
Articles on similar topics can be found in the following collections

- Ophthalmologic surgical procedures (1223)
- Lens and zonules (807)
- Angle (1006)
- Glaucoma (988)
- Intraocular pressure (1002)
- Anterior chamber (26)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
Disappearance of eyelid xanthelasma following oral simvastatin (Zocor)

The major risk factors for coronary heart disease include smoking, elevated blood pressure, and elevated serum cholesterol. Risk reduction starts with identification of those at risk and then alteration of factors such as discontinuation of smoking, lowering of blood pressure, and reduction of serum cholesterol. Patients who should have a blood cholesterol testing include those with family history of premature coronary heart disease or hyperlipidaemia, personal history of coronary heart disease, or clinical evidence of elevated lipids with features of xanthelasma, corneal arcus under age 50 years, and cutaneous xanthomas at any age.1 Two of the latter clinical features are ophthalmic and detection relies on the ophthalmologist.

Xanthelasma appear as multiple yellow placoid lesions in the pericorneal skin and represent a concentration of lipocytes in the dermis.2 There are numerous methods to manage the cosmetic appearance of xanthelasmas which typically involves surgical excision or laser ablation.3 We report a novel approach to management using oral cholesterol lowering medication and patience.

Case report

In 1992, a 68 year old male smoker with a history of hypertension and elevated serum cholesterol was referred for evaluation of a newly diagnosed iris mass. On examination, the visual acuity was 20/20 in both eyes. The mass was diagnosed as a benign iris nevus and observation was advised. Coincidental bilateral medial canthal and upper and lower eyelid xanthelasmas were detected (fig 1A). The largest xanthelasma measured 16 mm in diameter. Observation was advised with tentative plan for surgical excision in the future. The patient was advised to continue his antihypertensive medications and anti-cholesterol medication (oral simvastatin (Zocor) 20 mg once daily). At the 6 month follow up the iris nevus was stable and the xanthelasma persisted. Yearly examinations were advised. The patient did not return for 10 years. Surprisingly, the xanthelasma had completely resolved, leaving no clinical trace of subcutaneous lipid (fig 1B). He continued on his medications and serum cholesterol was normal.

Comment

In the Lipids Research Clinics Program Prevalence Study, xanthelasma and corneal arcus were associated with increased levels of serum cholesterol and low density lipoprotein cholesterol (LDL-C), especially in young males.4 People with either lesion had increased odds of having type IIa dyslipoproteinemia. Adjusted odds ratios for ischaemic heart disease in participants with xanthelasma and corneal arcus were generally increased. The study concluded that the clinical findings of xanthelasma or corneal arcus, especially in young people, helped to identify those with plasma lipoprotein abnormalities.4

Management of patients with elevated LDL-C include both low cholesterol diet and cholesterol lowering medications, the most popular of which are the statins. There are currently five statin drugs on the market in the United States and these include lovastatin (Mevacor, Altocor), simvastatin (Zocor), pravastatin (Pravachol), fluvastatin (Lescol), and atorvastatin (Lipitor). The major effect of these medications is to lower LDL-C by slowing down the production of cholesterol and by increasing the liver’s ability to metabolise the LDL-C in the blood. Statins reduce LDL-C by approximately 40% and produce a modest increase in high density lipoprotein-cholesterol (HDL-C). These medications are given daily in the evening to take advantage of the fact that the body makes more cholesterol at night. Statins reduce measured blood LDL-C within 4–6 weeks. In a study of 20 536 patients, this resulted in long-term reduction in coronary heart disease, stroke, and mortality.5

Simvastatin is derived synthetically from a fermentation product of Aspergillus terreus. Simvastatin is hydrolysed by an inhibitor of an enzyme responsible for cholesterol synthesis. In the Multicenter Anti-Atheroma Study, simvastatin slowed the progression of atherosclerosis, measured by vascular stenosis diameter on angiography, and decreased significantly the development of new lesions.6

To our knowledge, there have been no previous reports on the effect of statins on eyelid xanthelasma. A PubMed search for keywords “statin and xanthelasma” and simvastatin and xanthelasma yielded no relevant publications. The management of eyelid xanthelasmas includes surgical excision, microsurgical inverted peeling, laser ablation and resurfacing, photodynamic using carbon dioxide laser, and application of bichloracetic acid. Patients with the highest recurrence rate are those with elevated cholesterol. These local treatments do not address possible systemic associations. By observations in this report, we suggest that serum cholesterol be evaluated and if elevated, oral statin combined with dietary cholesterol restriction might result in resolution of xanthelasmas over time, but, more importantly, reduction of patient cardiac risk.

References

New onset diplopia: 14 years after retinal detachment surgery with a hydrogel scleral buckle

In 1979, the hydrogel explant (Miragel, Waltham, MA, USA) was introduced as a scleral buckling material in the surgical management of retinal detachment.1 It was widely used in the 1980s and early 1990s as it was initially believed to be well tolerated, less prone to infection, and easy to manipulate.2 However, long term complications related to swelling and fragmentation of the explant have been reported over recent years,3 resulting in discontinuation of its use in 1999.

Case report

A 36 year old healthy man presented on 2003 with symptoms of mild right ocular discomfort. Past ocular history included a right retinal detachment repair 14 years previously, using a 907 (3 x 5 mm) Miragel scleral buckle (Miragel, Medical Instruments Research Associates, Waltham, MA, USA), sutured to the inferior sclera. On examination, visual acuity was 20/120 right and 20/20 left. There was no diplopia or limitation of eye movements. What was thought to be a small conjunctival cyst was noted inferiorly but, otherwise, the ocular examination was unremarkable and the retina was tacile.

A year later (2004), he presented with increasing marked right ocular discomfort and diplopia in all fields. His visual acuity was unchanged, but there was marked restriction of elevation and reduction in adduction of the right eye and binocular diplopia in all fields of gaze. A tense swelling of the inferior conjunctiva was noted (fig 1, top), intraocular pressure was normal, and the retina was flat with a moderate anterior bucket effect. Computed tomography (CT) (fig 1, bottom) demonstrated a right orbital circumferential soft tissue mass surrounding lower half of the globe and a small area of calcification on the inferotemporal retina.

In our case, there was a profound increase in the explant volume during a 14 year period. The resulting diplopia and restriction of extraocular movement as well as the clinical evaluation mimicked a giant orbital inclusion cyst. The correct diagnosis was only made intraoperatively. Scleral thinning and necrosis as seen in our case has been reported previously,7 resulting in intraoperative vitreous leak after removal of the expanded explant.8 In our patient, there was an area of thinned sclera, but the surrounding calcification and the early removal of the explant prevented vitreous leak.

It is important to note that patients who have undergone scleral buckling with hydrogel explants before 1995 are at risk of developing this complication. Symptoms of progressive diplopia, pain, and restriction of extraocular muscle movement in these patients should also raise the possibility of explant expansion. The assistance of a retinal surgeon may sometimes be required because of the increased risk of scleral thinning and leakage of liquid vitreous intraoperatively.

References

8 Metz HS, Rose S, Burkat C. Late-onset progressive strabismus associated with a hydrogel scleral buckle. J AAPOS 2004;8:72–3

Intraoperative photograph showing the swollen hydrogel buckle under the inferior rectus muscle (arrow). Bottom: The hydrogel buckle after removal.

Figure 1 Top: Clinical photograph of the right eye showing bulging of the inferior fornix. Bottom: Coronal computed tomographic scan showing a circumferential soft tissue mass surrounding lower half of the globe and a small area of calcification on the inferotemporal retina.

Figure 2 Top: Intraoperative photograph showing the swollen hydrogel buckle under the inferior rectus muscle (arrow). Bottom: The hydrogel buckle after removal.

Inverse globe retraction syndrome complicating recurrent pterygium

Often larger and more aggressive than the original lesion, recurrent pterygia can cause visual symptoms that are most often secondary to their mechanical effects on the cornea.9 We report a case of inverse globe retraction syndrome (that is, retraction during abduction) due to the restrictive effect of a recurrent pterygium and the management of this complication.

Case report

A 28 year old man without a medical history or ocular symptoms underwent pterygium excision in his left eye with a superotemporal conjunctival autograft and intraoperative mitomycin C. Three weeks postoperatively, he noted a feeling of pressure in the left eye...
Comment
Inverse globe retraction syndrome is rare.1,2 It has been reported as being caused by medial rectus abnormality,3 innervational misdirection,4 and secondary to restriction from traumatic tissue capture in the medial orbital wall.5 The current case demonstrates another cause for the syndrome, globe restriction as a result of a leash effect from aggressive pterygium recurrence. The risk of pterygium recurrence after initial pterygium removal is minimised by the technique of conjunctival autograft with adjunctive mitomycin C; however, because aggressive recurrence is still possible initial pterygium surgery should only be performed for patients with significant cosmetic and/or functional concerns. For the management of inverse globe retraction syndrome complicating recurrent pterygium in this case, the use of amniotic membrane as a tissue spacer permitted excellent functional improvement.

References

Seeing is not believing
We describe a case of posterior cortical atrophy presenting with progressive visuoperceptual and visuospatial difficulties, but with no abnormalities on standard ophthalmological examination.

Case report
The patient, a 53 year old right handed woman, with well controlled primary generalised epilepsy, presented to her optometrist with a 1 year history of deterioration in vision. She had particular difficulties with walking downstairs and following text while reading. She could read 6/12×2 RE (with −0.75−0.25×90 correction) and 6/12×3 (with −0.75×90 correction) LE. With +2.25 correction she could read N5 slowly with each eye. On subsequent ophthalmological review no significant abnormality was found on examination and no specific diagnosis was made.

Over the following months her vision deteriorated. She reported difficulties following a line while writing and was unable to tell when a glass was full when pouring a drink. Her husband thought that she was unable to see things in her peripheral vision. This culminated in her crashing her car. She did not have any memory difficulties, she had preserved insight, and there had been no change in personality.

On admission to our unit her visual acuity was 6/18 RE and 6/12 LE with the above correction. She was able to read slowly at N5 corrected with each eye but was unable to name any of the Ishihara plate numbers including the test plate, despite being able to name the colours, trace the outline of the numbers with her finger, and read numbers in normal print. Confrontation visual fields were essentially full although she was slow to recognise objects in her peripheral visual fields owing to an apparent narrowing of attention to foveal vision and had optic ataxia, in that she was unable to localise in space, by pointing, objects placed in her peripheral visual fields. On Goldmann perimetry her visual fields appeared somewhat constricted, probably related to her difficulties with attention, but, importantly, no hemianopia was demonstrated (fig 1). Pupillary responses were normal as was fundal examination. On eye movement testing she had broken smooth pursuit eye movements, although she was able to generate voluntary saccades. The rest of the neurological examination was unremarkable.

Her mini-mental state examination score was 28/30. She had some deficits in verbal abstract reasoning and made occasional phonemic errors in speech. She had mild dyscalculia and dyspraxia, but she was able to differentiate left from right and name body parts. She had mild memory impairment, although these were mainly in tasks requiring visual input. She demonstrated simultanagnosia in that she was unable to see the whole of a picture and only described parts of it.

On testing with the cortical vision screening test she passed the hue discrimination test, the word reading test, face perception test, the crowding test of letter reading and was able to detect the presence of a circle in the shape detection test but was unsure what to say if it was not present. On the symbol

Figure 1 Goldmann perimetry (V4e and II2e).
which has been reported before in similar of her other visuoperceptual difficulties, normal colour vision, is probably a reflection slow, near vision. Her inability to recognise visuospatial ability, given her good, albeit acuity may have been related to her poor cognitive deficits. Her poor distance visual.

Comment
This woman therefore presented with progressive visuoperceptual and visuospatial difficulties, but had no abnormalities on ophthalmological examination. She had some features of Balint’s syndrome (that is, simultanagnosia and optic ataxia) and other cognitive deficits. Her poor distance visual acuity may have been related to her poor visuospatial ability, given her good, albeit slow, near vision. Her inability to recognise any of the Ishihara plates, with otherwise normal colour vision, is probably a reflection of her other visuoperceptual difficulties, which has been reported before in similar patients, although difficulty with figure-ground discrimination cannot be excluded.

Posterior cortical atrophy is a clinical and radiological diagnosis based upon the presence of occipitoparietal abnormalities with initially preserved occipitotemporal (face and colour recognition) and anterior cerebral function. It is thought to be as a result of Alzheimer’s disease, in most cases, although the syndrome has been described with other pathologies—for example, subcortical gliosis, Creutzfeld-Jakob disease, and progressive multifocal leukoencephalopathy. Although it is rare, it should be suspected in any patient presenting with visuoperceptual or visuospatial difficulties in the absence of any signs on standard ophthalmological examination. Screening tests for higher visual function deficits can then be employed.

The corollary of this is that a patient with an established diagnosis of dementia should be tested for disorders of higher visual function, because a patient with otherwise mild cognitive deficits may still be driving.

S J Hickman, D Alvares, H Crewes, R J Wise, A N Gale
Royal Free Hospital, Pond Street, London NW3 2QG, UK
Correspondence to: Simon J Hickman, Royal Free Hospital, Pond Street, London NW3 2QG, UK; simonhickman@btinternet.com
doi: 10.1136/bjo.2004.054429
Accepted for publication 28 September 2004

References

Radial optic neurotomy in combined cilioretinal artery and central retinal vein occlusion
Combined cilioretinal artery and central retinal vein occlusion (CRVO) is a rare clinical finding first described by Oosterhuis. The pathogenesis of this condition is not well established and remains controversial. Most reports postulate that the initial CRVO causes an elevation of the intraluminal capillary pressure and induces a consequently reduced perfusion pressure at the arterial side. Since the perfusion pressure of the cilioretinal artery is lower than the central artery, it becomes relatively occluded. Recently Opremcak et al described radial optic neurotomy (RON) involving pars plana vitrectomy (PPV) and radial incision of the optic nerve to treat CRVO. We report this new surgical approach in a patient with combined cilioretinal artery occlusion and CRVO.

Case report
A healthy 64 year old woman complained of unilaterally blurred vision for the past 3 days. Her visual acuity (VA) was 20/200 in the right eye (RE) and 20/20 in the left eye (LE). The anterior segment in both eyes was unremarkable on slit lamp examination. Fundus examination RE demonstrated a whitening of the macula corresponding to an area supplied by a cilioretinal artery. The retinal veins were dilated, accompanied by adjacent retinal haemorrhages (fig 1A). The fundus of the left eye appeared normal. Fluorescein angiography (FA) RE revealed a delayed arteriovenous (AV) perfusion time of 13 seconds. Systemic evaluation of the patient did not reveal any general disease. Although treated systemically with corticosteroids and low dose heparin for 4 weeks, she developed CRVO with severe disc oedema, extensive dilatation of the retinal veins, radial oriented intraretinal haemorrhages, and cotton wool spots (fig 1B). On FA there was a reduced perfusion time of the cilioretinal artery in addition to the typical...
signs of CRVO (fig 2A). Based on positive results of RON in CRVO, we offered this treatment to our patient. After she signed an informed consent, RON was performed with two radial cuts at the nasal edge of the optic disc. After 2 days disc oedema was significantly reduced with sharp visible disc margins. Two months postoperatively the retinal haemorrhages, cotton wool spots, and disc oedema had almost disappeared and her VA improved to 20/25 RE (fig 1C). FA demonstrated a physiological AV perfusion time of less than 3 seconds and no signs of an occluded cilioretinal artery (fig 2B).

Comment

Combined cilioretinal artery occlusion and CRVO are discussed as a separate clinical entity in the literature,4,5 and its treatment by RON has not been described. Opremcak et al postulated that a surgical decompression of the optic disc and scleral ring by RON may contribute to an improved venous perfusion in CRVO. Our patient demonstrated additional signs of an arterial occlusion with delayed filling of the cilioretinal artery in the macula, which may induce permanent functional loss. The underlying pathomechanism of CRVO remain unknown, current discussion leans towards an intraluminal occlusion by a thrombus, increased extravasal pressure, or a combination of both as possible causes.7 In addition the therapeutic effect of RON is also questionable. It remains unclear as to whether RON causes a decompression of the optic disc increasing the ocular blood flow or induces the formation of new chorioretinal shunt vessel.2 In our case the goal of RON was to reduce the capillary pressure, therefore increasing the perfusion in the cilioretinal artery and thus improving central vision. Patients with combined occlusive AV disease may benefit from RON by improving their haemodynamic perfusion pressure, retinal anatomy, and consecutive central visual function.

5 Mennel, K Droutsas, C H Meyer, J C Schmidt, P Kroll
Department of Ophthalmology, Philippus-University Marburg, Germany

Correspondence to: Stefan Mennel, MD, Department of Ophthalmology, Philippus-University Marburg, Robert-Koch-Strasse 4, 35037 Marburg, Germany; stefan.mennel@lycos.com
doi: 10.1136/bjo.2004.054858
Accepted for publication 20 October 2004

Financial support: none.
Proprietary interest: none.

References


Value based medicine

In a fine recent editorial, Drs Melissa and Gary Brown raised issues at the nexus of health policy and clinical science. As utility assessment is relatively new to the visual sciences, understanding both the assumptions behind this work and the consequences of relaxing those assumptions is essential for the conduct of high quality research and appropriate interpretation of the results.

The use of community elicited utilities (that is, including people without the disease in the elicitation study) in economic evaluation should be given more than minimal consideration. Metaeconomic evaluations are intended to inform health policy makers by assessing the value society places on the cure or prevention of disease. Community based utilities typically reflect larger estimates of utility loss than those elicited from patients and result in a more favourable analysis of the cost-effectiveness of preventive interventions than those relying on patient elicited utilities. At the same time, estimating community elicited utilities requires the development of easily understood scenarios to assist community members in understanding their life with the disease, after leading investigators prefer to rely on patient elicited utilities. Rather than dismiss the community elicited approach, economic evaluation in ophthalmology would be greatly facilitated by development of a catalogue of community elicited utilities related to old disease developed through the standard gamble or time trade-off methods or responses to health status questionnaires that include algorithms to estimate health utilities.

While the Browns caution against the use of functionally based health related quality of life instruments (for example, the NEI-VFQ) in economic evaluation, we would like to offer an alternative explanation for this concern. Most disease specific instruments are based in psychometric theory and designed to measure change in the patient’s self reported health status in investigator defined domains. Domain scores do not reflect the importance the respondent assigns to the activities, but scoring algorithms developed by the instrument designer. The result is a metric that is often meaningful to clinicians but does not reflect the value the patient or society places on the health state. This limits generalisability across disease groups, as well as investigators’ ability to comment on the most efficient method to screen for, or treat, an ophthalmic condition affecting multiple areas of physical, mental, or emotional function.

Finally, the standard gamble elicitation method should not be dismissed off handly. More frequent use of the time trade-off reflects the method’s intuitive appeal rather than theoretical superiority. As opposed to the time trade-off in which the anchor event (typically, death, blindness, etc) recur at some future, in the standard gamble the event is immediate. This provides an estimate of the person’s risk preference unconfounded by time. The time trade-off consistently results in higher estimates of utility loss than the standard gamble,1 potentially resulting in an overestimation of the cost-effectiveness of treatment or prevention.

We hope that our comments will help future work to be pragmatic and theoretically sound. This is necessary if we are to properly characterise the appropriateness of our methods as well as the value of our findings.

S M Kymes
Washington University School of Medicine,
Department of Ophthalmology and Visual Sciences,
660 South Euclid, Campus Box 8096,
Saint Louis, MO 63116, USA

K D Frick
Johns Hopkins Bloomberg School of Public Health
Department of Health Policy and Management,
Baltimore, MD, USA

Correspondence to: Dr Steven Kymes, Washington University School of Medicine Department of Ophthalmology and Visual Sciences, 660 South Euclid, Campus Box 8096, Saint Louis, MO 63116, USA; kymes@wrsr.wustl.edu
doi: 10.1136/bjo.2004.063784
Accepted for publication 3 December 2004
Cystoid macular oedema with trypan blue use

We read with interest the article by Gouws et al.\(^1\) on the apparent increased incidence of cystoid macular oedema (CME) in phaco-emulsification patients when trypan blue was used to stain the anterior capsule.

Trypan blue has been commonly used in both anterior and posterior segment surgeries.\(^2\) If trypan blue does cause macular toxicity, its risk should theoretically be higher when used in posterior segment surgeries. However, studies on the use of trypan blue, both in the anterior\(^3\) and posterior\(^4\) segments, did not show apparent toxicity.

Thus, it would be appreciated if the authors could clarify whether other subclinical confounders were assessed in their study, including: (1) other causes of CMO such as diabetes, uveitis, and prostaglandin use; (2) operating time since phototoxicity from the operating microscope is a risk factor for CMO development. It appears that only operations for patients in group B were performed by one surgeon, if operations for patients in group A (with trypan blue use) were done by trainees, the operative time is expected to be longer; (3) whether all patients received a fundus examination with dilated pupil after the operation. If these were only performed in patients with suboptimal visual acuities, the incidence of CMO may be underestimated.

Finally, we concur with the authors’ view that we should try all means in terms of minimising any theoretical toxicities of trypan blue. It is our routine to actively remove trypan blue with the bimanual irrigation aspiration system as soon as the anterior capsule has been stained. It is very effective and the potential toxicities may be reduced.

Authors’ reply

We thank Drs Kymes and Frick for their excellent letter regarding utility analysis as a health related quality of life instrument. We agree that the use of primarily function based quality of life instruments such as the NEI-VFQ-25 may result in missing many important variables in the quality of life arena, as well as limit applicability across all diseases.\(^1\) In contrast, preference based quality of life instruments such as the NEI-VFQ-25 may result in missing many important variables in the quality of life arena, as well as limit applicability across all diseases.\(^1\) In contrast, we and others agree that the use of primarily function based utility analysis, which is easier for patients to comprehend and also is found that the time trade-off methodology is preferred to value-based analysis.\(^2\) However, studies on the use of time trade-off and standard gamble utility analysis, we have found that the time trade-off method of utility has greater test-retest rater reliability than standard gamble methodology. In our experience, time trade-off, standard gamble and visual analogue scales have not been successfully used.\(^3\)

Concerning the use of time trade-off and standard gamble utility analysis, we have found that the time trade-off methodology is easier for patients to comprehend and also is more sensitive to milder health states since there is risk aversion to the consequence of immediate death associated with the standard gamble method.\(^4\) Froberg and Kane\(^5\) have also shown that the time trade-off method of utility has greater test-retest reliability, intra-rater reliability and inter-rater reliability than standard gamble methodology. In our experience, time trade-off and standard gamble utilities generally demonstrate better construct validity\(^6\) and a wider range between pre-intervention and post-intervention values than standard gamble utilities, thus resulting in more favourable cost utility analysis, rather than less favourable analyses.

With regard to quality of life respondents, we remain firm in our adherence to the fact that a basic pillar of value based medicine is the use of utility values obtained from respondents with a health state in question.\(^7\) We have found that utility value diminution in patients who actually have age related macular degeneration ranges from 10% to 750% greater than the decrement estimated by treating ophthalmologists for the same condition.\(^8\) This has been noted as well for non-ophthalmological health states.\(^9\) We disagree that community utility values generally overestimate the degree to which a disease decreases quality of life. In contrast, we and others\(^10\) have noted that community and provider participants asked to evaluate the quality of life associated with a health state using utility value analysis generally underestimate the decrement in quality of life compared to patients with that health state. In essence, patients who have lived with a health state are those best able to ascertain the quality of life associated with that health state. And it is usually worse than others imagine.

In conclusion, we thank Kymes and Frick for their interest and comments and look forward to additional awareness in the arena of value based medicine. As increasing numbers of those who allocate healthcare resources become aware that value based medicine allows for higher quality care (by incorporating quality of life parameters that evidence based primary clinical trials often ignore) and the most efficient use of resources, it will have a considerably greater role in the delivery of cost effective, quality healthcare. When that takes place, all will benefit.

Cystoid macular oedema with trypan blue use

We read with interest the article by Gouws et al.\(^1\) on the apparent increased incidence of cystoid macular oedema (CME) in phaco-emulsification patients when trypan blue was used to stain the anterior capsule. Trypan blue has been commonly used in both anterior and posterior segment surgeries.\(^2\) If trypan blue does cause macular toxicity, its risk should theoretically be higher when used in posterior segment surgeries. However, studies on the use of trypan blue, both in the anterior\(^3\) and posterior\(^4\) segments, did not show apparent toxicity.

Thus, it would be appreciated if the authors could clarify whether other subclinical confounders were assessed in their study, including: (1) other causes of CMO such as diabetes, uveitis, and prostaglandin use; (2) operating time since phototoxicity from the operating microscope is a risk factor for CMO development. It appears that only operations for patients in group B were performed by one surgeon, if operations for patients in group A (with trypan blue use) were done by trainees, the operative time is expected to be longer; (3) whether all patients received a fundus examination with dilated pupil after the operation. If these were only performed in patients with suboptimal visual acuities, the incidence of CMO may be underestimated.

Finally, we concur with the authors’ view that we should try all means in terms of minimising any theoretical toxicities of trypan blue. It is our routine to actively remove trypan blue with the bimanual irrigation aspiration system as soon as the anterior capsule has been stained. It is very effective and the potential toxicities may be reduced.

References


Authors’ reply

We thank Lam et al for their interest. In response to their comments, we state in the article and demonstrated in figures 1B and C, the effect persists when co-morbidity such as diabetes is removed.

Both groups’ surgery was performed by the same surgeon and did not have juniors attached to the list.

PostScript
This retrospective study on a unique cohort of patients provided us with the opportunity to demonstrate a potential side effect with the use of trypan blue. A prospective trial is required to control for all the variables and confirm or refute our findings.

P Gowes, P Simcock
Conquest Hospital, Hastings, UK

Correspondence to: Peter Simcock, West of England Eye Unit, Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK; psimcock@hotmail.com
doi: 10.1136/bjo.2004.069765
Accepted for publication 23 February 2005

Reference

BOOK REVIEW

The History of Moorfields Eye Hospital, Volume III

Like John Mortimer’s book of a similar title this third volume of the history of Moorfields Eye Hospital is an affectionate but critical look back at the hospital that has been a major influence in many ophthalmologists’ training and subsequent practice. The volume is written in a positive upbeat style but also describes some of the faults and difficulties that have beset it in the past four decades. In a complex organisation such as a hospital there are inevitable inefficiencies and problems with personalities but the author has wisely stuck to the facts and has plotted the course of the management of the hospital in a very readable way; he has sensibly avoided petty confrontations and offers a lucid outline of the course of Britain’s flagship ophthalmic hospital.

The two previous histories of Moorfields described times past when ophthalmic practice changed only gradually and political upheaval was minor. The current author has been in the unique position of being involved with Moorfields throughout the 40 years he describes. Given the turmoil, both professional and managerial, that has engulfed the delivery of health care during this period he was fortunate that many of the individuals involved with the hospital were available for interview, thus providing first hand accounts of the good and bad times that affected the hospital. The various chapters outline lucidly the clinical and political changes of the time; Moorfields represents in microcosm all the disciplines that have been subjected. One special feature of the period described is that it also covers the first 40 years following the foundation of the Institute of Ophthalmology and the not always easy relationship between the hospital and the institute is recorded both openly and tactfully.

The book comprises a number of chapters outlining the various aspects of the hospital development—for example, clinical, managerial, financial, etc. The first chapter is an overview involving all aspects of the hospital during the 40 years from 1963 to 2003. It provides a concise synopsis of all the forces bearing on the hospital; not only clinical but also in terms of research, teaching, and political upheaval. Indeed, for those younger ophthalmologists entering the profession at the present time it gives a concise overview of those political influences that have shaped the lives of the NHS and its staff during recent decades.

As the author points out in his preface the subsequent chapters take up the issues raised in the first chapter and analyse them in more detail. If one, therefore, picks up the book and reads it cover to cover there is a strong repetitive element but it was not really the author’s intention that the book should be necessarily read in this way. Each of the later chapters is written in a stand alone fashion dealing with clinical progress, academic development, research, management, and finance so that some repetition is inevitable. The major characters in the story of Moorfields development are given due weight; particularly Professor Barrie Jones, under whose influence Moorfields progressed from a rather slow moving organisation to the establishment of all the subspecialist services we know today.

Apart from rather a large number of nautical metaphors such as “calm waters,” “stormy seas,” and a few petty errors of detail, such as dates, this volume is a good read, particularly if approached as the author intended. He himself has made major contributions to the standing of Moorfields Eye Hospital and the book is written in the typically clear and polished style, reminiscent of his own scientific contributions.

R Grey
Bristol Eye Hospital, Lower Maudlin Street, Bristol BS1 2LX, UK; linda.clayton@ubht.swest.nhs.uk

CORRECTIONS

In the letter entitled, Norrie disease and peripheral venous insufficiency (Br J Ophthalmol 2004;88:1475) the ordering of the authors was incorrect. The correct order is Michaelides M, Luthert PJ, Cooling R, Firth H, Moore AT. The journal apologises for this error.

doi: 10.1136/bjo.2005.58032corr1

Owing to an author error the name of one of the authors of the paper entitled, Long term effect on IOP of a stainless steel glaucoma drainage implant (Ex-PRESS) in combined surgery with phacoemulsification, which appeared in the April issue of the journal (Br J Ophthalmol 2005;89:423–9) was omitted (S Gandolfi). The author list should be C Traverso, F De Feo, A Messas-Kapal, P Denis, S Levartovsky, E Sellem, F Badalà, Z Zagorski, A Bron, S Gandolfi, M Belkin. S Gandolfi is at the Clinica Ocucistica, University of Parma, Italy.

doi: 10.1136/bjo.2005.42356corr1

NOTICES

Worldwide clinical trials for new technique for early detection of eye disease

A unique new non-invasive technique for high resolution optical imaging of the eye is receiving global acclaim. By combining two high-resolution imaging technologies, the new technique provides doctors with 3-D images of the retina, macula and the optic nerve.